Search

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction

936 results found

Article

Baker & Hostetler LLP | USA | 13 Feb 2020

FDA Turns Its Attention to Celebrity Influencers

New studies to explore the power of endorsement and disclosure techniques

Article

Bristows | USA, European Union | 7 Feb 2020

Transatlantic echoes: FTC and FDA focus on competition in biologics

For those who don’t make a practice of reading press releases from the US regulatory bodies, a recent joint statement by the US Food & Drug

Article

McDermott Will & Emery | USA | 4 Feb 2020

Anticompetitive Conduct in Biologics - An Enforcement Priority with FTC and FDA

Today the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) released joint guidance concerning competition for biologics

Article

Hogan Lovells | USA | 29 Jan 2020

FDA may accept DMFs for electronics and software components of drug-led combination products

On Monday, the FDA published the draft guidance, “Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or

Article

McDermott Will & Emery | USA | 29 Jan 2020

Inherent Claim Limitation Necessarily Present in the Prior Art Invalidates Patent

Addressing the issue of obviousness, the US Court of Appeals for the Federal Circuit affirmed the district court’s finding that a patent was invalid

Article

McDermott Will & Emery | USA | 28 Jan 2020

Available Now - 2019 Digital Health Year in Review

Throughout the past year, the healthcare and life science industries experienced a proliferation of digital health innovation that challenged

Article

Kelley Drye & Warren LLP | USA | 22 Jan 2020

House Subcommittee Holds Hearing on Current Cannabis Policies

On January 15, the Subcommittee on Health of the Committee on Energy and Commerce held its first ever legislative hearing to address federal cannabis

Article

Dechert LLP | USA | 21 Jan 2020

Dechert Survey: Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies

Securities class action litigation on the whole remained at a steady high in 2019, and life sciences companies were, once again, popular targets of

Article

McDermott Will & Emery | USA | 16 Jan 2020

US Office of Management and Budget Issues a Memorandum Calling for Agency Plans From Federal Government Agencies

On January 7, 2020, the Director of the US Office of Management and Budget (OMB) issued a Draft Memorandum (the Memorandum) to all federal

Article

McDermott Will & Emery | USA | 15 Jan 2020

Inherency Can Be Used in Obviousness Analysis to Supply Missing Limitation

Finding that inherency can be used to show the presence of a missing claim limitation, the US Court of Appeals for the Federal Circuit affirmed a

Previous page 1 2 3 ...